DOI: 10.12890/2025_005632
When less could be more: successful treatment of granulomatous lymphocytic interstitial lung disease with azathioprine
Authors
analauralopez.ra@gmail.com
Keywords
Common variable immunodeficiency, GLILD, interstitial lung disease, azathioprine, follicular T helper cells, CD21low B cellsAbstract
Introduction: Interstitial lung disease is a major complication in patients with common variable immunodeficiency. There are some publications that try to shed light on the pathophysiology of this non-infectious complication, most of them highlight the role of follicular T cells and CD21low B cells. Moreover, there are no guidelines based on randomized controlled studies on the treatment of patients with interstitial lung disease and the published case series or small uncontrolled studies describe a wide range of response rates to treatment. In this scenario, the decisions are based on expert opinion rather than on robust scientific evidence. This could lead to potential biases associated with expert opinion based on a small number of patients.
Case description: We present the case of an adult patient with common variable immunodeficiency and interstitial lung disease. He did not receive rituximab due to an adverse reaction and underwent treatment with azathioprine, achieving prolonged remission after treatment discontinuation.
Discussion: If T-cell involvement could be the main underlying cause of this complication, treatment targeting T-cells may possibly be an effective therapeutic option. Our case, complemented with a physiopathology review, suggests a beneficial effect of azathioprine that warrants further research.
Conclusion: It is important to keep in mind that patients with common variable immunodeficiency are a heterogeneous group, so no single treatment will be the best for all of them. It is necessary to review the rationale for the increasing use of anti-CD20 drugs in non-infectious complications in patients with common variable immunodeficiency. Such use is based on expert recommendations and not on randomized, controlled studies with quantitative endpoints.
References
- Ho HE, Cunningham-Rundles C. Non-infectious complications of common variable immunodeficiency: updated clinical spectrum, sequelae, and insights to pathogenesis. Front Immunol 2020;11:149. doi: 10.3389/fimmu.2020.00149
- Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood 2012;119:1650-1657. doi: 10.1182/blood-2011-09-377945
- Lamers OAC, Smits BM, Leavis HL, de Bree GJ, Cunningham-Rundles C, Dalm VASH, et al. Treatment strategies for GLILD in common variable immunodeficiency: a systematic review. Front Immunol 2021;12:606099. doi: 10.3389/fimmu.2021.606099
- Maglione PJ, Gyimesi G, Cols M, Radigan L, Ko HM, Weinberger T, et al. BAFF-driven B cell hyperplasia underlies lung disease in common variable immunodeficiency. JCI Insight 2019;4:e122728. doi: 10.1172/jci.insight.122728
- Unger S , Seidl M, van Schouwenburg P, Rakhmanov M, Bulashevska A, Frede N, et al. The TH1 phenotype of follicular helper T cells indicates an IFN-y-associated immune dysregulation in patients with CD21low common variable immunodeficiency. J Allergy Clin Immunol 2018;141:730-740. doi: 10.1016/j.jaci.2017.04.041
- Turpin D, Furudoi A, Parrens M, Blanco P, Viallard JF, Duluc D. Increase of follicular helper T cells skewed toward a Th1 profile in CVID patients with non-infectious clinical complications. Clin Immunol 2018;197:130-138. doi: 10.1016/j.clim.2018.09.006
- Friedmann D, Unger S, Keller B, Rakhmanov M, Goldacker S, Zissel G, et al. Bronchoalveolar lavage fluid reflects a TH1-CD21low B-cell interaction in CVID-related interstitial lung disease. Front Immunol 2021;11:616832. doi: 10.3389/fimmu.2020.616832
- Coraglia A, Galassi N, Fernández Romero DS, Juri MC, Felippo M, Malbrán A, de Bracco MM. Common Variable Immunodeficiency and Circulating Tfh. J Immunol Res 2016;2016:4951587. doi: 10.1155/2016/4951587
